Anti-ACP7/ PAPL/ PAPL1 functional antibody
Anti-ACP7/ PAPL/ PAPL1 functional antibody for cell culture, ELISA & in-vivo assay
Go to ACP7/ACP7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE0634-Ab-1/ GM-Tg-hg-SE0634-Ab-2 | Anti-Human ACP7 monoclonal antibody | Human |
| GM-Tg-rg-SE0634-Ab-1/ GM-Tg-rg-SE0634-Ab-2 | Anti-Rat ACP7 monoclonal antibody | Rat |
| GM-Tg-mg-SE0634-Ab-1/ GM-Tg-mg-SE0634-Ab-2 | Anti-Mouse ACP7 monoclonal antibody | Mouse |
| GM-Tg-cynog-SE0634-Ab-1/ GM-Tg-cynog-SE0634-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ACP7 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE0634-Ab-1/ GM-Tg-felg-SE0634-Ab-2 | Anti-Feline ACP7 monoclonal antibody | Feline |
| GM-Tg-cang-SE0634-Ab-1/ GM-Tg-cang-SE0634-Ab-2 | Anti-Canine ACP7 monoclonal antibody | Canine |
| GM-Tg-bovg-SE0634-Ab-1/ GM-Tg-bovg-SE0634-Ab-2 | Anti-Bovine ACP7 monoclonal antibody | Bovine |
| GM-Tg-equg-SE0634-Ab-1/ GM-Tg-equg-SE0634-Ab-2 | Anti-Equine ACP7 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-SE0634-Ab-1/ GM-Tg-hg-SE0634-Ab-2; GM-Tg-rg-SE0634-Ab-1/ GM-Tg-rg-SE0634-Ab-2; GM-Tg-mg-SE0634-Ab-1/ GM-Tg-mg-SE0634-Ab-2; GM-Tg-cynog-SE0634-Ab-1/ GM-Tg-cynog-SE0634-Ab-2; GM-Tg-felg-SE0634-Ab-1/ GM-Tg-felg-SE0634-Ab-2; GM-Tg-cang-SE0634-Ab-1/ GM-Tg-cang-SE0634-Ab-2; GM-Tg-bovg-SE0634-Ab-1/ GM-Tg-bovg-SE0634-Ab-2; GM-Tg-equg-SE0634-Ab-1/ GM-Tg-equg-SE0634-Ab-2 |
| Products Name | Anti-ACP7 monoclonal antibody |
| Format | mab |
| Target Name | ACP7 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-ACP7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-SE0634-Ag-1 | Recombinant multi-species ACP7/ PAPL/ PAPL1 protein |
Target information
| Target ID | GM-SE0634 |
| Target Name | ACP7 |
| Gene ID | 390928,101744,687403,695532,484514,101092474,521171,100066750 |
| Gene Symbol and Synonyms | ACP7,C330005M16Rik,PAPL,PAPL1 |
| Uniprot Accession | Q6ZNF0 |
| Uniprot Entry Name | ACP7_HUMAN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000183760 |
| Target Classification | N/A |
The target: ACP7, gene name: ACP7, also named as PAPL, PAPL1. Purple acid phosphatases (PAPs), including PAPL, are a family of binuclear metallohydrolases that have been identified in plants, animals, and fungi (Flanagan et al., 2006 [PubMed 16793224]).[supplied by OMIM, Mar 2008].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

